# Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01636401** · PHASE3 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.**

## Conditions studied

- COPD

## Interventions

- **DRUG:** aclidinium bromide 400 μg
- **DRUG:** aclidinium bromide placebo

## Key facts

- **NCT ID:** NCT01636401
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** — (—)
- **Last updated:** 2013-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01636401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01636401, "Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01636401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*